ProShares Ultra Bloomberg Natural Gas

United States Natural Gas

GraniteShares 1.5x Short NVDA Daily ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Semicondct Bear 3X ETF

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Direxion Technology Bear 3X Shares

Bank Of Montreal

Direxion Daily FTSE China Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

GraniteShares 1.5x Long NVDA Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Volatility Shares Trust 2x Ether ETF

ProShares Ultra Semiconductors

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily Technology Bull 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

iShares Ethereum Trust ETF

Siyata Mobile Inc. Common Shares

Edible Garden AG Incorporated Common Stock

Eyenovia Inc. Common Stock

D-Wave Quantum Inc. Common Shares

Mind Medicine (MindMed) Inc. Common Shares

COMPASS Pathways Plc American Depository Shares

LOBO EV TECHNOLOGIES LTD. Ordinary shares

ScanTech AI Systems Inc. Common stock

Classover Holdings Inc. Class B Common Stock

Pony AI Inc. American Depositary Shares

NWTN Inc. Class B Ordinary Shares

Protagenic Therapeutics Inc. Common Stock

Brainstorm Cell Therapeutics Inc. Common Stock

ASP Isotopes Inc. Common Stock

Incannex Healthcare Limited American Depositary Shares

Canaan Inc. American Depositary Shares

Freight Technologies Inc. Ordinary Shares

CoreWeave Inc. Class A Common Stock

Trip.com Group Limited American Depositary Shares

SCWorx Corp. Common Stock

Click here to get full coverage on With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Finance

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest  Yahoo Finance

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Finance

Click here to get full coverage on Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Leerink Partners Upgrades Compass Therapeutics (CMPX)  Nasdaq

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Click here to get full coverage on Spotlight On Three Promising Penny Stocks In May 2025 - simplywall.st

Spotlight On Three Promising Penny Stocks In May 2025  simplywall.st

Spotlight On Three Promising Penny Stocks In May 2025 - simplywall.st

Click here to get full coverage on CMPX Stock Price and Chart — NASDAQ:CMPX - TradingView

CMPX Stock Price and Chart — NASDAQ:CMPX  TradingView

CMPX Stock Price and Chart — NASDAQ:CMPX - TradingView

Click here to get full coverage on Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus

Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News  GuruFocus

Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus

Click here to get full coverage on Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers  Seeking Alpha

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha

Click here to get full coverage on Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire

Compass Therapeutics to Participate in Upcoming May Investor Events  GlobeNewswire

Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire

Click here to get full coverage on Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025  Insider Monkey

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Click here to get full coverage on Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns  simplywall.st

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st

Click here to get full coverage on Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025 - Yahoo Finance

Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025  Yahoo Finance

Why Compass Therapeutics Inc (CMPX) Is Skyrocketing So Far In 2025 - Yahoo Finance

Click here to get full coverage on Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq

Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation  Nasdaq

Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq

Click here to get full coverage on Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ)  Seeking Alpha

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting  GlobeNewswire

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire

Click here to get full coverage on Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Yahoo Finance

Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025?  Yahoo Finance

Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Yahoo Finance

Click here to get full coverage on Insider Purchase: CHIEF ACCOUNTING OFFICER of $CMPX Buys 20,000 Shares - Nasdaq

Insider Purchase: CHIEF ACCOUNTING OFFICER of $CMPX Buys 20,000 Shares  Nasdaq

Insider Purchase: CHIEF ACCOUNTING OFFICER of $CMPX Buys 20,000 Shares - Nasdaq

Click here to get full coverage on Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus

Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX)  GuruFocus

Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus

Click here to get full coverage on Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?  Nasdaq

Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq

Click here to get full coverage on Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo

Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5?  Yahoo

Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo

Click here to get full coverage on Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer - GlobeNewswire

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer  GlobeNewswire

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer - GlobeNewswire

Click here to get full coverage on H.C. Wainwright maintains Compass stock Buy rating, $24 target - Investing.com

H.C. Wainwright maintains Compass stock Buy rating, $24 target  Investing.com

H.C. Wainwright maintains Compass stock Buy rating, $24 target - Investing.com

Click here to get full coverage on Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Yahoo Finance

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer  Yahoo Finance

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Yahoo Finance

Click here to get full coverage on Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - GlobeNewswire

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer  GlobeNewswire

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - GlobeNewswire

Click here to get full coverage on Top 3 High-Momentum Companies Analysts Are Still Bullish On - MarketBeat

Top 3 High-Momentum Companies Analysts Are Still Bullish On  MarketBeat

Top 3 High-Momentum Companies Analysts Are Still Bullish On - MarketBeat

Click here to get full coverage on Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025  Insider Monkey

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey

Click here to get full coverage on Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update  GlobeNewswire

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewswire

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum  GlobeNewswire

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewswire

Click here to get full coverage on Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha

Compass Therapeutics stock rises on trial win (CMPX:NASDAQ)  Seeking Alpha

Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Compass Therapeutics, Inc. SEC 10-Q Report - TradingView

Compass Therapeutics, Inc. SEC 10-Q Report  TradingView

Compass Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ) - Seeking Alpha

Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ)  Seeking Alpha

Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView

Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating  TradingView

Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView

Click here to get full coverage on Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks

Compass Therapeutics Reports Positive Phase 2/3 Trial Results  TipRanks

Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks

Click here to get full coverage on Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate - Yahoo Finance

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate  Yahoo Finance

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate - Yahoo Finance

Click here to get full coverage on Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer  Benzinga

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Click here to get full coverage on 10 Hottest Smid-Cap Stocks So Far In 2025 - Insider Monkey

10 Hottest Smid-Cap Stocks So Far In 2025  Insider Monkey

10 Hottest Smid-Cap Stocks So Far In 2025 - Insider Monkey

Click here to get full coverage on Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - Nasdaq

Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why  Nasdaq

Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why - Nasdaq

Click here to get full coverage on Compass Therapeutics price target lowered to $10 from $12 at Guggenheim - MSN

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim  MSN

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim - MSN

Click here to get full coverage on BlackRock, Inc. Increases Stake in Compass Therapeutics Inc - GuruFocus

BlackRock, Inc. Increases Stake in Compass Therapeutics Inc  GuruFocus

BlackRock, Inc. Increases Stake in Compass Therapeutics Inc - GuruFocus

Click here to get full coverage on Compass Therapeutics, Inc. SEC 10-K Report - TradingView

Compass Therapeutics, Inc. SEC 10-K Report  TradingView

Compass Therapeutics, Inc. SEC 10-K Report - TradingView

Click here to get full coverage on This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday  Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Click here to get full coverage on This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday  Benzinga

This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Click here to get full coverage on Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update  GlobeNewswire

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on The Temperature-Regulation of Pseudomonas aeruginosa cmaX-cfrX-cmpX Operon Reveals an Intriguing Molecular Network Involving the Sigma Factors AlgU and SigX - Frontiers

The Temperature-Regulation of Pseudomonas aeruginosa cmaX-cfrX-cmpX Operon Reveals an Intriguing Molecular Network Involving the Sigma Factors AlgU and SigX  Frontiers

The Temperature-Regulation of Pseudomonas aeruginosa cmaX-cfrX-cmpX Operon Reveals an Intriguing Molecular Network Involving the Sigma Factors AlgU and SigX - Frontiers

Click here to get full coverage on CMPX 2024 - HPAC Magazine

CMPX 2024 - HPAC Magazine

Click here to get full coverage on What’s Hot in Hydronics: at CMPX Live with Siggy & The Bean - HPAC Magazine

What’s Hot in Hydronics: at CMPX Live with Siggy & The Bean  HPAC Magazine

What’s Hot in Hydronics: at CMPX Live with Siggy & The Bean - HPAC Magazine

Click here to get full coverage on Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market - Business Wire

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market  Business Wire

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market - Business Wire

Click here to get full coverage on Record-setting CMPX Prepares Industry For Future - Canadian Consulting Engineer

Record-setting CMPX Prepares Industry For Future  Canadian Consulting Engineer

Record-setting CMPX Prepares Industry For Future - Canadian Consulting Engineer

Click here to get full coverage on Canada’s HVAC and plumbing expo returns in March 2024 - Construction Canada

Canada’s HVAC and plumbing expo returns in March 2024  Construction Canada

Canada’s HVAC and plumbing expo returns in March 2024 - Construction Canada

Click here to get full coverage on NAVAC to Showcase Portfolio of HVAC Equipment at CMPX - PHCP Pros

NAVAC to Showcase Portfolio of HVAC Equipment at CMPX  PHCP Pros

NAVAC to Showcase Portfolio of HVAC Equipment at CMPX - PHCP Pros

Click here to get full coverage on Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc. - Business Wire

Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.  Business Wire

Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc. - Business Wire

Click here to get full coverage on CMPX Attracts Record Student Attendance - PHCP Pros

CMPX Attracts Record Student Attendance  PHCP Pros

CMPX Attracts Record Student Attendance - PHCP Pros

Click here to get full coverage on CMPX 2016: Plumbing expo attendance grows - Construction Canada

CMPX 2016: Plumbing expo attendance grows  Construction Canada

CMPX 2016: Plumbing expo attendance grows - Construction Canada

Click here to get full coverage on Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD  Defense World

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

Click here to get full coverage on Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World

Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00  Defense World

Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World

Click here to get full coverage on Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital - Defense World

Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital  Defense World

Compass Therapeutics Inc. (CMPX)

Price Chart

Key Statistics

Technicals

About CMPX

Latest News

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Finance

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Spotlight On Three Promising Penny Stocks In May 2025 - simplywall.st

Advanced Charts

Top Gainers

Top Losers